Literature DB >> 29758299

Autophagy regulates apoptosis by targeting NOXA for degradation.

Jingchao Wang1, Danrui Cui1, Shanshan Gu1, Xiaoyu Chen1, Yanli Bi1, Xiufang Xiong1, Yongchao Zhao2.   

Abstract

Apoptosis and autophagy mutually regulate various cellular physiological and pathological processes. The crosstalk between autophagy and apoptosis is multifaceted and complicated. Elucidating the molecular mechanism of their crosstalk will advance the therapeutic applications of autophagy for treating cancer and other diseases. NOXA, a BH3-only member of the BCL-2 family, was reported to induce apoptosis and promote autophagy. Here, we report that autophagy regulates apoptosis by targeting NOXA for degradation. Inhibiting autophagy increases NOXA protein levels by extending the protein half-life. NOXA accumulation effectively suppresses tumor cell growth by inducing apoptosis, which is further enhanced when p53 is present. Mechanistically, NOXA is hijacked by p62 as autophagic cargo, and its three lysine residues at the C-terminus are necessary for NOXA degradation in lysosomes. Taken together, our study demonstrates that NOXA serves as a bridge in the crosstalk between autophagy and apoptosis and implies that autophagy inhibitors could be an effective therapy for cancer, especially wild-type p53-containing cancer.
Copyright © 2018 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anticancer; Apoptosis; Autophagy; Crosstalk; Degradation; NOXA

Mesh:

Substances:

Year:  2018        PMID: 29758299     DOI: 10.1016/j.bbamcr.2018.05.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  8 in total

1.  Downregulation of miRNA-21 and cancer stem cells after chemotherapy results in better outcome in breast cancer patients.

Authors:  Shailendra Dwivedi; Puneet Pareek; Jeewan Ram Vishnoi; Praveen Sharma; Sanjeev Misra
Journal:  World J Stem Cells       Date:  2022-04-26       Impact factor: 5.247

2.  Fusobacterium nucleatum Facilitates Apoptosis, ROS Generation, and Inflammatory Cytokine Production by Activating AKT/MAPK and NF-κB Signaling Pathways in Human Gingival Fibroblasts.

Authors:  Wenyan Kang; Zhilong Jia; Di Tang; Zhanwei Zhang; Hui Gao; Kunlun He; Qiang Feng
Journal:  Oxid Med Cell Longev       Date:  2019-10-13       Impact factor: 6.543

3.  SCFβ-TrCP-mediated degradation of TOP2β promotes cancer cell survival in response to chemotherapeutic drugs targeting topoisomerase II.

Authors:  Jianfeng Shu; Danrui Cui; Ying Ma; Xiufang Xiong; Yi Sun; Yongchao Zhao
Journal:  Oncogenesis       Date:  2020-02-03       Impact factor: 7.485

4.  PRIMA‑1met induces autophagy in colorectal cancer cells through upregulation of the mTOR/AMPK‑ULK1‑Vps34 signaling cascade.

Authors:  Xiao-Lan Li; Jianbiao Zhou; Chen-Jing Xia; Han Min; Zhong-Kai Lu; Zhi-Rong Chen
Journal:  Oncol Rep       Date:  2021-04-13       Impact factor: 3.906

5.  DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells.

Authors:  Yanli Bi; Xiaoyu Chen; Bajin Wei; Linchen Wang; Longyuan Gong; Haomin Li; Xiufang Xiong; Yongchao Zhao
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

6.  P90 ribosomal S6 kinase confers cancer cell survival by mediating checkpoint kinase 1 degradation in response to glucose stress.

Authors:  Ying Ma; Danrui Cui; Linchen Wang; Yue Wang; Fei Yang; Hui Pan; Longyuan Gong; Minrun Zhang; Xiufang Xiong; Yongchao Zhao
Journal:  Cancer Sci       Date:  2021-11-03       Impact factor: 6.716

Review 7.  Double agents of cell death: novel emerging functions of apoptotic regulators.

Authors:  Heather M Lamb
Journal:  FEBS J       Date:  2020-04-11       Impact factor: 5.542

8.  Cell Death Triggered by the Autophagy Inhibitory Drug 3-Methyladenine in Growing Conditions Proceeds With DNA Damage.

Authors:  Javier Chicote; Víctor J Yuste; Jacint Boix; Judit Ribas
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.